The IL3 Knockout KYSE-30 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population featuring disruption of the IL3 gene in the human esophageal squamous cell carcinoma cell line KYSE-30. This polyclonal pool, generated via NHEJ repair after Cas9 cleavage, provides a heterogeneous loss-of-function model that avoids clonal selection bias. It is designed for investigating IL3-dependent signaling in a non-hematopoietic malignancy context, enabling study of cytokine-mediated tumor cell biology and microenvironment interactions.
KYSE-30 is a widely used human ESCC line derived from a well-differentiated tumor of a Japanese patient. Exhibiting epithelial morphology and characteristic genetic alterations, it serves as a relevant model for studying oncogenic signaling, drug response, and tumor progression. The cell line’s robust in vitro growth and manipulability make it an excellent host for gene knockout studies, facilitating dissection of molecular pathways in esophageal cancer.
IL3 is a hematopoietic cytokine that binds to the IL3RA/CD123 and CSF2RB/??c receptor complex, activating JAK2-mediated phosphorylation of STAT5, AKT1, and MAPK1/ERK2. These cascades promote cell survival and proliferation via downstream targets such as BCL2 and MYC. Upstream regulators include TCR activation, NFAT, NF-??B, AP-1, and TNF-??, while adaptors SHC and GRB2 link receptor activation to the MAPK pathway. IL3 signaling thus orchestrates critical checkpoints in hematopoietic cell fate.
In KYSE-30 ESCC cells, IL3 may be ectopically expressed, influencing tumor cell-autonomous pathways or paracrine crosstalk with the microenvironment. Knocking out IL3 allows rigorous assessment of its contributions to JAK/STAT and PI3K/AKT signaling within an epithelial cancer framework. The polyclonal nature captures phenotypic diversity, enabling studies on how IL3 loss affects proliferation, migration, and sensitivity to pathway-targeted therapeutics.
Applications include tumor microenvironment analyses, cytokine signaling dissection, and drug screening against the IL3-IL3R axis. Representative assays: ELISA for IL3, immunoblotting for phospho-STAT5/AKT/ERK, RT-qPCR for downstream targets, and functional assays like proliferation and migration. RNA-seq can reveal transcriptome-wide changes. For further information, custom projects, or validation inquiries, contact Ascent Research.
